Actos Settlement In Sight As First Threshold Crossed
This article was originally published in PharmAsia News
Executive Summary
More than 95% of eligible US claimants have decided to take up Takeda's offer of no fault financial resolution of product liability claims against its former blockbuster Actos, triggering the first steps towards a settlement.
You may also be interested in...
Melior, Bukwang Seek Diabetes Edge With Novel Insulin Sensitizer
MLR-1023, a repositioned oral compound being developed for type 2 diabetes by Melior and Bukwang, is set to move into Phase IIb in the US and South Korea, and the firms are looking to its novel mechanism of action, improved tolerability and efficacy to carve a niche in a highly competitive sector.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.